[OPR-132] KYRIOS clinical trial: Tracking the immune response to SARS-CoV-2
mRNA vaccines in an open-label multicenter study in participants with
relapsing multiple sclerosis treated with ofatumumab s.c.
[EPR-159] Patient reported perspectives on disease burden and early signs of
progression in multiple sclerosis in Germany (data collection
MSPerspectives)
Effectiveness and Tolerability of Ofatumumab Versus First-line
Disease-modifying Treatments in Early Relapsing Multiple Sclerosis
Patients: Phase 3b STHENOS Study Design
Long term Efficacy of Siponimod Treatment for up to 5 Years in
Patients with Secondary Progressive Multiple Sclerosis: Analysis of
the EXPAND Extension Study
Siponimod Slows Physical Disability Progression and Decline in
Cognitive Processing Speed in SPMS Patients with Active Disease: A
Post Hoc Analysis of the EXPAND Study
Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection
Risk in Relapsing Multiple Sclerosis Patients from the Phase 3
ASCLEPIOS I and II Trials